Dashboard
PDUFA
PDUFA History
Dilution Watch
Downside Radar
Missed Milestones
Earnings
Big Movers
Blog
🎤 Upcoming Biotech Conferences
Loading conferences...
Free to browse, no account needed
Track infectious disease catalysts with approval-probability scores and free alerts.
Infectious Disease Biotech Pipeline: Antivirals, Vaccines & Anti-Infectives
Every infectious disease program BioRadar tracks across 138 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 798 infectious disease drug programs across 138 public companies, with 2 upcoming FDA decisions in this area. The most active companies by program count are NVAX, GILD, ENTA, VIR, EBS.
798Drug programs
138Companies
192In Phase 3
2Upcoming FDA dates
Upcoming FDA decisions in Infectious Disease
Companies with infectious disease programs
NVAX
80 programs
GILD
59 programs
ENTA
40 programs
VIR
37 programs
EBS
35 programs
ASMB
30 programs
ICLR
25 programs
INVA
23 programs
INO
21 programs
VALN
19 programs
ARCT
18 programs
PCVX
18 programs
ABUS
13 programs
ARWR
13 programs
ALGS
12 programs
ALT
12 programs
AVIR
12 programs
INSM
12 programs
GOVX
11 programs
SPRO
10 programs
BCRX
9 programs
BNTX
9 programs
IVVD
8 programs
MIRM
8 programs
ABCL
7 programs
AIM
7 programs
IBRX
7 programs
IMDX
7 programs
MRK
7 programs
RDHL
7 programs
CORT
6 programs
MEDP
6 programs
PHAT
6 programs
TRAW
6 programs
ALDX
5 programs
MDGL
5 programs
OPK
5 programs
SCYX
5 programs
SGMT
5 programs
SIGA
5 programs
CRMD
4 programs
GRFS
4 programs
HRMY
4 programs
IFRX
4 programs
LGND
4 programs
ABVX
3 programs
ALNY
3 programs
COCP
3 programs
IBO
3 programs
IMCR
3 programs
IMRN
3 programs
IQV
3 programs
IVA
3 programs
LABT
3 programs
LPCN
3 programs
LQDA
3 programs
RFL
3 programs
SBFM
3 programs
SVRA
3 programs
ACXP
2 programs
ADMA
2 programs
ADPT
2 programs
AMRN
2 programs
ASBP
2 programs
BLRX
2 programs
CMMB
2 programs
COLL
2 programs
CRVS
2 programs
DVA
2 programs
FULC
2 programs
IMUX
2 programs
KMDA
2 programs
MCRB
2 programs
MESO
2 programs
MGNX
2 programs
PRME
2 programs
PULM
2 programs
PYPD
2 programs
SABS
2 programs
SMMT
2 programs
SPRY
2 programs
TEVA
2 programs
TTRX
2 programs
VRAX
2 programs
XTLB
2 programs
ZLAB
2 programs
ABBV
1 program
ABT
1 program
AMGN
1 program
AMRX
1 program
ATYR
1 program
AZN
1 program
BHC
1 program
BIOA
1 program
CANF
1 program
CLNN
1 program
CLRB
1 program
CPIX
1 program
CRDL
1 program
CRL
1 program
DTIL
1 program
EDSA
1 program
ENLV
1 program
EOCN
1 program
GALT
1 program
HRTX
1 program
IMNM
1 program
IMNN
1 program
INMB
1 program
IONS
1 program
IPHA
1 program
IRLA
1 program
JAZZ
1 program
KNSA
1 program
LKFT
1 program
LSTA
1 program
MREO
1 program
MTNB
1 program
NKTR
1 program
OCGN
1 program
ORMP
1 program
PDSB
1 program
PHAR
1 program
RIGL
1 program
ROIV
1 program
RPRX
1 program
RXRX
1 program
SNY
1 program
SRPT
1 program
SXTP
1 program
TAK
1 program
TLSA
1 program
TVGN
1 program
VCRE
1 program
VERA
1 program
VERU
1 program
VKTX
1 program
VSTM
1 program
Phase 3 infectious disease programs (192)
| Ticker | Drug | Indication |
|---|---|---|
| ABCL | LY3853113 | COVID-19 |
| ABCL | LY3819253 | COVID-19 |
| ABCL | LY3832479 | COVID-19 |
| ABCL | Bamlanivimab | COVID-19 |
| ABCL | Etesevimab | COVID-19 |
| ABVX | ABX203 therapeutic Hepatitis B vaccine t | Chronic Hepatitis B |
| ALDX | ADX-102 Ophthalmic Solution (0.5%) | Non-infectious Anterior Uveitis |
| ALDX | Vehicle of ADX-102 Ophthalmic Solution | Non-infectious Anterior Uveitis |
| ALT | Pemvidutide | Metabolic Dysfunction-Associated Steatohepatitis ( |
| AMGN | Inebilizumab | Autoimmune Hepatitis |
| AMRN | Icosapent ethyl (IPE) | COVID19 |
| AMRX | Phenazopyridine Hydrochloride Tables, US | Uncomplicated Urinary Tract Infections |
| ARCT | ARCT-2303 | COVID-19 |
| ARCT | Influenza vaccine | COVID-19 |
| ARCT | Influenza vaccine, adjuvanted | COVID-19 |
| ARCT | Astra Zeneca COVID-19 vaccine | COVID-19 Vaccines |
| ARCT | ARCT-154 Self-Amplifying RNA SARS-CoV-2 | COVID-19 Vaccines |
| AVIR | Bemnifosbuvir-Ruzasvir | HEPATITIS C VIRUS CHRONIC INFECTION |
| AVIR | Sofosbuvir-Velpatasvir | HEPATITIS C VIRUS CHRONIC INFECTION |
| AVIR | Bemnifosbuvir-Ruzasvir (BEM/RZR) | HEPATITIS C VIRUS CHRONIC INFECTION |
| AVIR | Sofosbuvir-Velpatasvir (SOF/VEL) | HEPATITIS C VIRUS CHRONIC INFECTION |
| AVIR | Bemnifosbuvir (BEM) | Severe Acute Respiratory Syndrome Coronavirus 2 (S |
| AVIR | RO7496998 | COVID-19 |
| AZN | Tozorakimab | Viral Lung Infection and Acute Respiratory Failure |
| BCRX | Peramivir | Influenza |
| BCRX | Peramivir 300mg | Influenza |
| BCRX | Peramivir 150mg | Influenza |
| BCRX | Oseltamivir | Influenza |
| BHC | Larsucosterol | Hepatitis |
| BNTX | BNT162b2 Vaccine | COVID-19 |
| BNTX | BNT162b2 | COVID-19 Vaccines |
| COLL | Saline solution | Sars-CoV-2 Infection |
| COLL | Evolocumab | Sars-CoV-2 Infection |
| CRDL | Cannabidiol, pharmaceutically produced w | COVID-19 |
| CRMD | Heparin | Central Line Associated Blood Stream Infections (C |
| CRVS | CPI-006 1 mg/kg + SOC | Covid-19 |
| CRVS | CPI-006 2 mg/kg + SOC | Covid-19 |
| EBS | ACAM2000 | Smallpox Vaccine Adverse Reaction |
| EDSA | SOC plus 15mg/kg EB05 IV | COVID-19 |
| EOCN | Aramchol free acid | Nonalcoholic Steatohepatitis (NASH) |
Phase 2 infectious disease programs (326)
| Ticker | Drug | Indication |
|---|---|---|
| ABBV | ABBV-382 | Human Immuno-deficiency Virus (HIV) Disease |
| ABCL | VIR-7831 | COVID-19 |
| ABCL | Bebtelovimab | COVID-19 |
| ABUS | AB-729 | Chronic Hepatitis b |
| ABUS | Peg-IFNα-2a | Chronic Hepatitis b |
| ABUS | Imdusiran (AB-729) | Chronic Hepatitis B |
| ABUS | Imdusiran | Hepatitis B, Chronic |
| ABUS | Durvalumab | Hepatitis B, Chronic |
| ABUS | SOC NrtI | Chronic Hepatitis B |
| ABUS | VBR | Chronic Hepatitis B |
| ABUS | ARB-001467 | Hepatitis B, Chronic |
| ABVX | ABX464 150mg | HIV Infections |
| ABVX | ABX464 50mg | HIV Infections |
| ACXP | Ibezapolstat | Clostridium Difficile Infection Recurrence |
| ACXP | Vancomycin | Clostridium Difficile Infection |
| ADMA | Hepatitis C Immune Globulin Intravenous | Sequelae of Viral Hepatitis |
| ADMA | RI-001 | Upper Respiratory Tract Infection |
| ADPT | Phage Therapy | Prosthetic Joint Infection |
| ADPT | Bacteriophage | Prosthetic Joint Infection |
| AIM | Alferon LDO | HIV Infections |
| AIM | poly I-poly C12U | HIV Seropositivity |
| AIM | Poly I:Poly C12U 50 ug | Influenza, Human |
| AIM | Poly I:Poly C12U 1250 ug | Influenza, Human |
| AIM | FluMist | Influenza, Human |
| AIM | Poly I:Poly C12U 200 ug | Influenza, Human |
| AIM | Poly I:Poly C12U 500 ug | Influenza, Human |
| ALDX | ADX-629 | Alcohol Hepatitis |
| ALDX | NS2 | Non-infectious Anterior Uveitis |
| ALDX | Prednisolone acetate ophthalmic suspensi | Non-infectious Anterior Uveitis |
| ALGS | ALG-000184 | Chronic Hepatitis B Infection |
| ALGS | TDF | Chronic Hepatitis B Infection |
| ALNY | pegylated interferon-alfa 2a | Chronic Hepatitis B |
| ALNY | VIR-2218 | Chronic Hepatitis B |
| ALT | HepTcell | Hepatitis B, Chronic |
| ALT | NasoVAX | Influenza |
| ARCT | Control vaccine younger adults | Influenza, Human |
| ARCT | Control vaccine older adults | Influenza, Human |
| ARCT | ARCT-2304 | Influenza, Human |
| ARCT | ARCT-154 | COVID-19 |
| ARCT | ARCT-021 | COVID-19 |
Phase 1 infectious disease programs (193)
| Ticker | Drug | Indication |
|---|---|---|
| ABUS | AB-101 | Chronic Hepatitis b |
| ABUS | Nucleos(t)ide Analogue | Chronic Hepatitis b |
| ABUS | AB-836 | Chronic Hepatitis |
| ABUS | TKM-100802 for Injection | Ebola Virus Infection |
| ABUS | TKM-100201 | Ebola Virus Infection |
| ALGS | ALG-097558 | COVID 19 |
| ALGS | Pevifoscorvir Sodium (ALG-000184) | Chronic Hepatitis B Infection |
| ALGS | Entecavir | Chronic Hepatitis B |
| ALGS | Midazolam | COVID-19 |
| ALGS | Itraconazole | COVID-19 |
| ALGS | ALG-097558 in solution formulation | COVID-19 |
| ALGS | ALG-097558 in tablet formulation | COVID-19 |
| ALGS | ALG-125755 | Chronic Hepatitis B |
| ALGS | ALG-020572 | Chronic Hepatitis B |
| ALGS | ALG-010133 | Chronic Hepatitis B |
| ALNY | ALN-HSD | Nonalcoholic Steatohepatitis |
| ALT | Warfarin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Atorvastatin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Ethinylestradiol and Levonorgestrel | NASH - Nonalcoholic Steatohepatitis |
| ALT | Digoxin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Metformin | NASH - Nonalcoholic Steatohepatitis |
| ALT | Pandemic Influenza Vaccine | Influenza A Subtype H5N1 Infection |
| ALT | FP-02.2 Vaccine | Hepatitis B |
| ARCT | Licensed Quadrivalent Vaccine for younge | Influenza, Human |
| ARCT | Licensed Quadrivalent Vaccine for older | Influenza, Human |
| ARCT | ARCT-2138 | Influenza, Human |
| ARWR | acetaminophen | Hepatitis B |
| ARWR | ARC-521 Injection | Hepatitis B |
| ASMB | ABI-4334 | Chronic Hepatitis B |
| ASMB | ABI-4334 Tablet | Chronic Hepatitis B |
| ASMB | ABI-H3733 | Chronic Hepatitis B |
| ASMB | ABI-H3733 Liquid Oral Dosage Form | Chronic Hepatitis B |
| ASMB | ABI-H3733 Solid Oral Dosage Form | Chronic Hepatitis B |
| ASMB | Vebicorvir (VBR) | Chronic Hepatitis B |
| ASMB | Esomeprazole | Chronic Hepatitis B |
| ASMB | Itraconazole | Chronic Hepatitis B |
| ASMB | Ethinyl Estradiol / Levonorgestrel | Chronic Hepatitis B |
| ASMB | Midazolam | Chronic Hepatitis B |
| ASMB | Rifampin | Chronic Hepatitis B |
| ASMB | ABI-H2158 Test Formulation | Chronic Hepatitis B |
Track infectious disease catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a infectious disease watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →